Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Clin Cancer Res. 2017 Jan 20;23(13):3343–3351. doi: 10.1158/1078-0432.CCR-16-2745

Figure 3. In vivo CLI of 90Y-DOTA-AR in VCaP tumor-bearing nude mice.

Figure 3

(A) Representative images of VCaP xenografts treated with 90Y-DOTA-AR alone (DOTA-AR) or combination of 90Y-DOTA-AR/VTP (Combination) at 4 and 24 hours p.i. (B) The graph demonstrates radiance for VCaP at 4 and 24 hours p.i. Tumor uptake of 90Y-DOTA-AR was not significantly different between two treatment groups at 4 hours p.i. (prior to VTP, p = 0.726, n = 13), but a 2.5-fold higher retention of the radioactivity was observed in the tumors of combination group at 24 hours p.i. (p < 0.0001, n = 10).